FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897597485> ?p ?o ?g. }

• W2897597485 endingPage "1294.e1" @default.
• W2897597485 startingPage "1285" @default.
• W2897597485 abstract "Background & AimsMany patients with gastroparesis are prescribed opioids for pain control, but indications for opioid prescriptions and the relationship of opioid use to gastroparesis manifestations are undefined. We characterized associations of use of potent vs weaker opioids and presentations of diabetic and idiopathic gastroparesis.MethodsWe collected data on symptoms, gastric emptying, quality of life, and health care resource use from 583 patients with gastroparesis (>10% 4-h scintigraphic retention) from the National Institute of Diabetes and Digestive and Kidney Diseases Gastroparesis Consortium, from January 2007 through November 2016. Patients completed medical questionnaires that included questions about opioid use. The opioid(s) were categorized for potency relative to oral morphine. Symptom severities were quantified by Patient Assessment of Upper Gastrointestinal Disorders Symptoms questionnaires. Subgroup analyses compared patients on potent vs weaker opioids and opioid effects in diabetic vs idiopathic etiologies.ResultsForty-one percent of patients were taking opioids; 82% of these took potent agents (morphine, hydrocodone, oxycodone, methadone, hydromorphone, buprenorphine, or fentanyl). Abdominal pain was the reason for prescription for 61% of patients taking opioids. Mean scores for gastroparesis, nausea/vomiting, bloating/distention, abdominal pain, and constipation scores were higher in opioid users (P ≤ .05). Opioid use was associated with greater levels of gastric retention, worse quality of life, increased hospitalization, and increased use of antiemetic and pain modulator medications compared with nonusers (P ≤ .03). Use of potent opioids was associated with worse gastroparesis, nausea/vomiting, upper abdominal pain, and quality-of-life scores, and more hospitalizations compared with weaker opioids (tapentadol, tramadol, codeine, or propoxyphene) (P ≤ .05). Opioid use was associated with larger increases in gastric retention in patients with idiopathic vs diabetic gastroparesis (P = .008).ConclusionsOpioid use is prevalent among patients with diabetic or idiopathic gastroparesis, and is associated with worse symptoms, delays in gastric emptying, and lower quality of life, as well as greater use of resources. Potent opioids are associated with larger effects than weaker agents. These findings form a basis for studies to characterize adverse outcomes of opioid use in patients with gastroparesis and to help identify those who might benefit from interventions to prevent opioid overuse. Many patients with gastroparesis are prescribed opioids for pain control, but indications for opioid prescriptions and the relationship of opioid use to gastroparesis manifestations are undefined. We characterized associations of use of potent vs weaker opioids and presentations of diabetic and idiopathic gastroparesis. We collected data on symptoms, gastric emptying, quality of life, and health care resource use from 583 patients with gastroparesis (>10% 4-h scintigraphic retention) from the National Institute of Diabetes and Digestive and Kidney Diseases Gastroparesis Consortium, from January 2007 through November 2016. Patients completed medical questionnaires that included questions about opioid use. The opioid(s) were categorized for potency relative to oral morphine. Symptom severities were quantified by Patient Assessment of Upper Gastrointestinal Disorders Symptoms questionnaires. Subgroup analyses compared patients on potent vs weaker opioids and opioid effects in diabetic vs idiopathic etiologies. Forty-one percent of patients were taking opioids; 82% of these took potent agents (morphine, hydrocodone, oxycodone, methadone, hydromorphone, buprenorphine, or fentanyl). Abdominal pain was the reason for prescription for 61% of patients taking opioids. Mean scores for gastroparesis, nausea/vomiting, bloating/distention, abdominal pain, and constipation scores were higher in opioid users (P ≤ .05). Opioid use was associated with greater levels of gastric retention, worse quality of life, increased hospitalization, and increased use of antiemetic and pain modulator medications compared with nonusers (P ≤ .03). Use of potent opioids was associated with worse gastroparesis, nausea/vomiting, upper abdominal pain, and quality-of-life scores, and more hospitalizations compared with weaker opioids (tapentadol, tramadol, codeine, or propoxyphene) (P ≤ .05). Opioid use was associated with larger increases in gastric retention in patients with idiopathic vs diabetic gastroparesis (P = .008). Opioid use is prevalent among patients with diabetic or idiopathic gastroparesis, and is associated with worse symptoms, delays in gastric emptying, and lower quality of life, as well as greater use of resources. Potent opioids are associated with larger effects than weaker agents. These findings form a basis for studies to characterize adverse outcomes of opioid use in patients with gastroparesis and to help identify those who might benefit from interventions to prevent opioid overuse." @default.
• W2897597485 created "2018-10-26" @default.
• W2897597485 creator A5000040784 @default.
• W2897597485 creator A5000745140 @default.
• W2897597485 creator A5001610749 @default.
• W2897597485 creator A5001848091 @default.
• W2897597485 creator A5002377198 @default.
• W2897597485 creator A5002882472 @default.
• W2897597485 creator A5004136854 @default.
• W2897597485 creator A5004402679 @default.
• W2897597485 creator A5004623320 @default.
• W2897597485 creator A5005028574 @default.
• W2897597485 creator A5006433297 @default.
• W2897597485 creator A5006620265 @default.
• W2897597485 creator A5007147188 @default.
• W2897597485 creator A5008114094 @default.
• W2897597485 creator A5008134598 @default.
• W2897597485 creator A5008668965 @default.
• W2897597485 creator A5009678693 @default.
• W2897597485 creator A5011561410 @default.
• W2897597485 creator A5012944536 @default.
• W2897597485 creator A5013221250 @default.
• W2897597485 creator A5013443210 @default.
• W2897597485 creator A5013465020 @default.
• W2897597485 creator A5013534331 @default.
• W2897597485 creator A5014174082 @default.
• W2897597485 creator A5016130443 @default.
• W2897597485 creator A5016655250 @default.
• W2897597485 creator A5018403450 @default.
• W2897597485 creator A5018608114 @default.
• W2897597485 creator A5019306105 @default.
• W2897597485 creator A5019907352 @default.
• W2897597485 creator A5020380734 @default.
• W2897597485 creator A5021341126 @default.
• W2897597485 creator A5022416484 @default.
• W2897597485 creator A5023705069 @default.
• W2897597485 creator A5025513141 @default.
• W2897597485 creator A5027063784 @default.
• W2897597485 creator A5027806481 @default.
• W2897597485 creator A5028133324 @default.
• W2897597485 creator A5028753266 @default.
• W2897597485 creator A5028885092 @default.
• W2897597485 creator A5029187488 @default.
• W2897597485 creator A5029368966 @default.
• W2897597485 creator A5030985342 @default.
• W2897597485 creator A5036053329 @default.
• W2897597485 creator A5036347033 @default.
• W2897597485 creator A5037818470 @default.
• W2897597485 creator A5041379402 @default.
• W2897597485 creator A5041878718 @default.
• W2897597485 creator A5046171742 @default.
• W2897597485 creator A5046799442 @default.
• W2897597485 creator A5046817260 @default.
• W2897597485 creator A5051677632 @default.
• W2897597485 creator A5056274446 @default.
• W2897597485 creator A5057243058 @default.
• W2897597485 creator A5066190474 @default.
• W2897597485 creator A5066891285 @default.
• W2897597485 creator A5069361158 @default.
• W2897597485 creator A5071143697 @default.
• W2897597485 creator A5073339338 @default.
• W2897597485 creator A5074870604 @default.
• W2897597485 creator A5075373863 @default.
• W2897597485 creator A5075913529 @default.
• W2897597485 creator A5079903988 @default.
• W2897597485 creator A5079952114 @default.
• W2897597485 creator A5080056103 @default.
• W2897597485 creator A5083754188 @default.
• W2897597485 creator A5084787883 @default.
• W2897597485 creator A5085261582 @default.
• W2897597485 creator A5088741303 @default.
• W2897597485 creator A5091779455 @default.
• W2897597485 date "2019-06-01" @default.
• W2897597485 modified "2023-10-18" @default.
• W2897597485 title "Opioid Use and Potency Are Associated With Clinical Features, Quality of Life, and Use of Resources in Patients With Gastroparesis" @default.
• W2897597485 cites W1976149361 @default.
• W2897597485 cites W1980190867 @default.
• W2897597485 cites W1985753348 @default.
• W2897597485 cites W1990747711 @default.
• W2897597485 cites W2007157748 @default.
• W2897597485 cites W2011934653 @default.
• W2897597485 cites W2014871043 @default.
• W2897597485 cites W2016375172 @default.
• W2897597485 cites W2017843863 @default.
• W2897597485 cites W2017968011 @default.
• W2897597485 cites W2026115311 @default.
• W2897597485 cites W2029445248 @default.
• W2897597485 cites W2029652174 @default.
• W2897597485 cites W2034053679 @default.
• W2897597485 cites W2037410387 @default.
• W2897597485 cites W2038519274 @default.
• W2897597485 cites W2046907939 @default.
• W2897597485 cites W2054038059 @default.
• W2897597485 cites W2060116619 @default.
• W2897597485 cites W2091697371 @default.
• W2897597485 cites W2093685229 @default.
• W2897597485 cites W2131778196 @default.
• W2897597485 cites W2140305247 @default.

• next